A network-based multi-target computational estimation scheme for anticoagulant activities of compounds

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Li, Qian ^a,b,d   Li, Xudong ^a   Li, Canghai ^c   Chen, Lirong ^a   Song, Jun ^c   Tang, Yalin ^b   Xu, Xiaojie ^a  

^a PEKING UNIVERSITY   (China)

^b INSTITUTE OF CHEMISTRY   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; ARGATROBAN INTERMEDIATE 1; ARGATROBAN INTERMEDIATE 2; ARGATROBAN INTERMEDIATE 3; ARGATROBAN INTERMEDIATE 4; ARGATROBAN INTERMEDIATE 5; ARGATROBAN INTERMEDIATE 6; BENZOFURAN DERIVATIVE; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; FANGQUINOLINE; FOLIC ACID; GLUTAMINE; LIENSININE; QUERCETIN; RUTOSIDE; SALVIANOLIC ACID A; SALVIANOLIC ACID B; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MOLECULAR DOCKING; PREDICTION; PROCESS DEVELOPMENT; VALIDATION STUDY; BLOOD CLOTTING; DRUG EFFECT; HUMAN;

ANTICOAGULANTS; BLOOD COAGULATION; HUMANS;

EID: 79952975593     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014774     Document Type: Article

References (65)

1. Mann KG, Butenas S, Brummel K, (2003) The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 23: 17-25.
2. Davie EW, Fujikawa K, Kisiel W, (1991) The Coagulation Cascade- Initiation, Maintenance, and Regulation. Biochemistry 30: 10363-10370.
3. Rester U, (2008) From virtuality to reality- Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Dev 11: 559-568.
4. Bender A, Mussa HY, Glen RC, Reiling S, (2004) Similarity searching of chemical databases using atom environment descriptors (MOLPRINT 2D): evaluation of performance. J Chem Inf Comput Sci 44: 1708-1718.
5. Sun H, (2008) Pharmacophore-based virtual screening. Curr Med Chem 15: 1018-1024.
6. Geppert H, Vogt M, Bajorath J, (2010) Current trends in ligand-based virtual screening: molecular representations, data mining methods, new application areas, and performance evaluation. J Chem Inf Model 50: 205-216.
7. Jenkins JL, Kao RYT, Shapiro R, (2003) Virtual screening to enrich hit lists from high-throughput screening: A case study on small-molecule inhibitors of angiogenin. Protein Struct Funct Genet 50: 81-93.
8. Mestres J, (2002) Virtual screening: a real screening complement to high-throughput screening. Biochem Soc Trans 30: 797-799.
9. Shoichet BK, (2004) Virtual screening of chemical libraries. Nature 432: 862-865.
10. Wei L, Yu J, (2008) Bioinformatics in China: A Personal Perspective. PLoS Comput Biol 4: e1000020.
11. Kontijevskis A, Prusis P, Petrovska R, Yahorava S, Mutulis F, et al. (2007) A Look Inside HIV Resistance through Retroviral Protease Interaction Maps. PLoS Comput Biol 3: e48.
12. Jenwitheesuk E, Horst JA, Rivas KL, Van Voorhis WC, Samudrala R, (2008) Novel paradigms for drug discovery: computational multitarget screening. Trends Pharmacol Sci 29: 62-71.
13. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M, (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
14. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL, (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
15. Kitano H, (2004) Biological robustness. Nat Rev Genet 5: 826-837.
16. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206.
17. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human disease network. Proc Natl Acad Sci U S A 104: 8685-8690.
18. Wu CB, Ying H, Grinnell C, Bryant S, Miller R, et al. (2007) Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 25: 1290-1297.
19. Ricklin D, Lambris JD, (2007) Complement-targeted therapeutics. Nat Biotechnol 25: 1265-1275.
20. Schuster S, Fell DA, Dandekar T, (2000) A general definition of metabolic pathways useful for systematic organization and analysis of complex metabolic networks. Nat Biotechnol 18: 326-332.
21. Wishart DS, (2008) DrugBank and its relevance to pharmacogenomics. Pharmacogenomics 9: 1155-1162.
22. Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, et al. (2008) Which aspects of HTS are empirically correlated with downstream success? Curr Opin Drug Discov Dev 11: 327-337.
23. Sakharkar MK, Li P, Zhong ZW, Sakharkar KR, (2008) Quantitative analysis on the characteristics of targets with FDA approved drugs. Int J Biol Sci 4: 15-22.
24. Wist AD, Berger SI, Iyengar R, (2009) Systems pharmacology and genome medicine: a future perspective. Genome Med 1: 11.
25. Auffray C, Chen Z, Hood L, (2009) Systems medicine: the future of medical genomics and healthcare. Genome Med 1: 2.
26. Agoston V, Csermely P, Pongor S, (2005) Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E Stat Nonlin Soft Matter Phys 71: 051909.
27. Kitano H, (2007) Innovation- A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 6: 202-210.
28. Stephen P, Vijayan R, Bhat A, Subbarao N, Bamezai RNK, (2008) Molecular modeling on pyruvate phosphate dikinase of Entamoeba histolytica and in silico virtual screening for novel inhibitors. J Comput-Aided Mol Des 22: 647-660.
29. Korcsmáros TS, Máté S, Böde C, Kovács IA, Csermely P, (2007) How to design multi-target drugs. Expert Opin Drug Discov 2: 799-808.
30. Stephanou A, McDougall SR, Anderson ARA, Chaplain MAJ, (2005) Mathematical modelling of flow in 2D and 3D vascular networks: Applications to anti-angiogenic and chemotherapeutic drug strategies. Math Comput Model 41: 1137-1156.
31. Spiro Z, Kovacs IA, Csermely P, (2008) Drug-therapy networks and the prediction of novel drug targets. J Biol 7: 20.
32. Qiao XB, Hou TJ, Zhang W, Guo SL, Xu XJ, (2002) A 3D structure database of components from Chinese traditional medicinal herbs. J Chem Inf Comp Sci 42: 481-489.
33. Tan F, Deng J, (2002) Analysis of the constituents and antisenile function of Achyranthes bidentata polysaccharides. Acta Bot Sin 44: 795-798.
34. Li Y, Xu C, Zhang QA, Liu JY, Tan RX, (2005) In vitro anti-Helicobacter pylori action of 30 Chinese herbel medicines used to treat ulcer diseases. J Ethnopharmacol 98: 329-333.
35. Satoh Y, Tashiro S, Satoh M, Fujimoto Y, Xu JY, et al. (1996) Studies on the bioactive constituents of Aurantii fructus immaturus. Yakugaku Zasshi 116: 244-250.
36. Halgren TA, (1996) Merck molecular force field. 1. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17: 490-519.
37. Adler M, Kochanny MJ, Ye B, Rumennik G, Light DR, et al. (2002) Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry 41: 15514-15523.
38. Tucker TJ, Brady SF, Lumma WC, Lewis SD, Gardell SJ, et al. (1998) Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J Med Chem 41: 3210-3219.
39. Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, et al. (1999) Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure 7: 989-996.
40. Zbinden KG, Banner DW, Ackermann J, D'Arcy A, Kirchhofer D, et al. (2005) Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett 15: 817-822.
41. Olivero AG, Eigenbrot C, Goldsmith R, Robarge K, Artis DR, et al. (2005) A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem 280: 9160-9169.
42. Tang J, Yu CL, Williams SR, Springman E, Jeffery D, et al. (2005) Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J Biol Chem 280: 41077-41089.
43. Huang MD, Syed R, Stura EA, Stone MJ, Stefanko RS, et al. (1998) The mechanism of an inhibitory antibody on TF-initiated blood coagulation revealed by the crystal structures of human tissue factor, Fab5G9 and TF center dot 5G9 complex. J Mol Biol 275: 873-894.
44. Dullweber F, Stubbs MT, Musil D, Sturzebecher J, Klebe G, (2001) Factorising ligand affinity: A combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J Mol Biol 313: 593-614.
45. Emsley J, Cruz M, Handin R, Liddington R, (1998) Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J Mol Biol 273: 10396-10401.
46. Ngo JCK, Huang M, Roth DA, Furie BC, Furie B, (2008) Crystal structure of human factor VIII: Implications for the formation of the factor IXa-factor VIIIa complex. Structure 16: 597-606.
47. Papagrigoriou E, McEwan PA, Walsh PN, Emsley J, (2006) Crystal structure of the factor XI zymogen reveals a pathway for transactivation. Nat Struct Mol Biol 13: 557-558.
48. Everse SJ, Spraggon G, Veerapandian L, Doolittle RF, (1999) Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide. Biochemistry 38: 2941-2946.
49. Yee VC, Pedersen LC, Letrong I, Bishop PD, Stenkamp RE, et al. (1994) Three-Dimensional Structure of a Transglutaminase: Human Blood Coagulation Factor XIII. Proc Natl Acad Sci U S A 91: 7296-7300.
50. Li XD, Hou TJ, Xu XJ, (2005) Comparative studies of 14 binding free energies scoring functions. Acta Phys-Chim Sin 21: 504-507.
51. Park H, Lee J, Lee S, (2006) Critical assessment of the automated AutoDock as a new docking tool for virtual screening. Proteins 65: 549-554.
52. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, et al. (2005) Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 33: D428-D432.
53. Latora V, Marchiori M, (2001) Efficient behaviour of small-world networks. Phys Rev Lett 87: 198701.
54. Csermely P, Agoston V, Pongor S, (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26: 178-182.
55. Davidson BL, (2003) Preparing for the new anticoagulants. J Thromb Thrombolysis 16: 49-54.
56. Rai R, Sprengeler PA, Elrod KC, Young WB, (2001) Perspectives on factor Xa inhibition. Curr Med Chem 8: 101-119.
57. Di Nisio M, Middeldorp S, Buller HR, (2005) Direct thrombin inhibitors. N Engl J Med 353: 1028-1040.
58. Kranjc A, Kikelj D, (2004) Dual inhibitors of the blood coagulation enzymes. Curr Med Chem 11: 2535-2547.
59. Nishio H, Ieko M, Nakabayashi T, (2008) New therapeutic option for thromboembolism-dabigatran etexilate. Expert Opin Pharmacother 9: 2509-2517.
60. Guertin KR, Choi YM, (2007) The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 14: 2471-2481.
61. Ortolani O, Caggiano M, Mannelli R, Gogliettino A, Tufano R, (1995) Protection from ischemia-reperfusion damage in patients with stroke: the role of rutin and GSH. Transplant Proc 27: 2877-2878.
62. Krupinski K, Breddin HK, Giedrojc J, Bodzenta-Lukaszyk A, Bielawiec M, (1995) Effects of 0-/-B-hydroxyethyl/rutoside on platelet function and thrombus formation in rat mesenteric vessels. Mater Med Pol 27: 39-42.
63. Shi CS, Huang HC, Wu HL, Kuo CH, Chang BI, et al. (2007) Salvianolic acid B modulates hemostasis properties of human umbilical vein endothelial cells. Thromb Res 119: 769-775.
64. Jiang R, Lau K, Hon P, Mak T, Woo K, et al. (2005) Chemistry and biological activities of caffeic acid derivatives from Salvia miltiorrhiza. Curr Med Chem 12: 237-246.
65. Mitsos A, Melas IN, Siminelakis P, Chairakaki AD, Saez-Rodriguez J, et al. (2009) Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data. PLoS Comput Biol 5: e1000591.